Zymeworks Management

Management criteria checks 2/4

Zymeworks' CEO is Ken Galbraith, appointed in Jan 2022, has a tenure of 2.33 years. total yearly compensation is $3.37M, comprised of 18.5% salary and 81.5% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth $203.86K. The average tenure of the management team and the board of directors is 1.3 years and 1.1 years respectively.

Key information

Ken Galbraith

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage	18.5%
CEO tenure	2.3yrs
CEO ownership	0.03%
Management average tenure	1.3yrs
Board average tenure	1.1yrs

Recent management updates

Recent updates

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

Zymeworks: A Roller Coaster Year

Jul 26

Zymeworks And The Blue Falcon Elucidation

May 17

Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 27

We Think Zymeworks (NYSE:ZYME) Can Afford To Drive Business Growth

Nov 17

Zymeworks: Drop Due To Low Differentiation Against Competition

Jul 05

Zymeworks: Oncology Drug Discovery Company With Major Big Pharma Deals

Dec 11

Zymeworks' zanidatamab nabs Breakthrough Therapy tag for biliary tract cancer

Nov 30

Zymeworks' zanidatamab an Orphan Drug in Europe for gastric cancer

Nov 19

CEO Compensation Analysis

How has Ken Galbraith's remuneration changed compared to Zymeworks's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$3m	US$625k	-US$119m
Sep 30 2023	n/a	n/a	US$205m
Jun 30 2023	n/a	n/a	US$186m
Mar 31 2023	n/a	n/a	US$173m
Dec 31 2022	US$7m	US$582k	US$124m
Sep 30 2022	n/a	n/a	-US$224m
Jun 30 2022	n/a	n/a	-US$237m
Mar 31 2022	n/a	n/a	-US$240m
Dec 31 2021	n/a	n/a	-US$212m
Sep 30 2021	n/a	n/a	-US$211m
Jun 30 2021	n/a	n/a	-US$223m
Mar 31 2021	n/a	n/a	-US$194m
Dec 31 2020	n/a	n/a	-US$181m
Sep 30 2020	n/a	n/a	-US$215m
Jun 30 2020	n/a	n/a	-US$173m
Mar 31 2020	n/a	n/a	-US$163m
Dec 31 2019	US$167k	n/a	-US$145m

Compensation vs Market: Ken's total compensation ($USD3.37M) is about average for companies of similar size in the US market ($USD3.42M).

Compensation vs Earnings: Ken's compensation has been consistent with company performance over the past year.

CEO

Ken Galbraith (60 yo)

2.3yrs

Tenure

US$3,374,876

Compensation

Mr. Kenneth H. Galbraith, also known as Ken, C. A., is Director of AudienceView Ticketing Corporation. He serves as Chairman of Zomp. He is Director of NeurAxon Inc. He is CEO & Chairman of the Board of Zy...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kenneth Galbraith	Chairman	2.3yrs	US$3.37m	0.034% $ 203.9k
Paul Moore	Chief Scientific Officer	1.8yrs	US$1.68m	0.010% $ 63.2k
Mark Hollywood	Executive VP and Head of Technical & Manufacturing Operations	no data	no data	no data
Daniel Dex	Senior VP	no data	no data	no data
Diana Papove	Senior Manager of Corporate Communications	no data	no data	no data
Lindsey Foulkes	Vice President of Corporate Development	no data	no data	no data
Laura O'Connor	Vice President of Human Resources & DEI	1.3yrs	no data	no data
Jeffrey Smith	Executive VP & Chief Medical Officer	no data	no data	no data
Josemund Menezes	Managing Director of Early-Stage Development for Asia Pacific	1.3yrs	no data	no data
John Fann	Senior Vice President of Process Sciences	less than a year	no data	no data
Ryan Dercho	Senior Director of Corporate Affairs	no data	no data	no data
Nina Weisser	Director of Multispecific Antibody Therapeutics	no data	no data	no data

1.3yrs

Average Tenure

55yo

Average Age

Experienced Management: ZYME's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kenneth Galbraith	Chairman	2.3yrs	US$3.37m	0.034% $ 203.9k
Hollings Renton	Independent Director	7.3yrs	US$264.00k	0% $ 0
Nancy Davidson	Independent Director	less than a year	US$441.02k	no data
Neil Gallagher	Director	less than a year	no data	no data
Kelvin Neu	Independent Director	4.2yrs	US$262.46k	0% $ 0
Susan Mahony	Lead Independent Director	4.9yrs	US$261.83k	0% $ 0
Alessandra Cesano	Independent Director	less than a year	no data	no data
Derek John Miller	Independent Director	1.1yrs	US$555.15k	0% $ 0
Troy Cox	Independent Director	4.9yrs	US$263.83k	0.011% $ 64.4k
Scott Platshon	Independent Director	less than a year	no data	no data
Carlos Campoy	Independent Director	less than a year	US$508.97k	0% $ 0

1.1yrs

Average Tenure

59yo

Average Age

Experienced Board: ZYME's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Zymeworks Management

Management criteria checks 2/4

Key information

Recent management updates

Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President

Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024

High number of new directors

Zymeworks Announces Appointment of Dr. Alessandra Cesano to Its Board of Directors

CEO & Chairman of the Board notifies of intention to sell stock

Zymeworks Inc. Announces Changes to its Board

Recent updates

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Zymeworks Inc. to Report Q1, 2024 Results on May 02, 2024

Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President

Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024

Consensus EPS estimates upgraded to US$0.88 loss, revenue downgraded

New minor risk - Profitability

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Zymeworks Inc. to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

High number of new directors

Zymeworks Inc. to Report Q4, 2023 Results on Mar 06, 2024

Zymeworks Announces Appointment of Dr. Alessandra Cesano to Its Board of Directors

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

CEO & Chairman of the Board notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Zymeworks Inc. Announces Changes to its Board

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zymeworks Inc. to Report Q3, 2023 Results on Nov 07, 2023

Zymeworks Inc., Annual General Meeting, Dec 07, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Zymeworks Inc. Appoints Carlos E. Campoy to the Board of Directors, Effective from June 30, 2023

Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Investor sentiment deteriorates as stock falls 16%

Zymeworks Inc. Announces Executive Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 16%

Insufficient new directors

Consensus EPS estimates fall by 10%

Consensus revenue estimates increase by 51%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Price target increased by 8.4% to US$13.73

Consensus revenue estimates increase by 18%

Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma

Consensus revenue estimates increase by 19%

Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer

Insider recently sold US$8.0m worth of stock

Consensus revenue estimates fall by 12%

Zymeworks Inc. Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

Consensus revenue estimates fall by 11%

Zymeworks Inc. Announces New Clinical Data for Zanidatamab in Her2+ /Hr+ Metastatic Breast Cancer Presented At 2022 Sabcs

Zymeworks Inc., Annual General Meeting, Dec 16, 2022

Consensus revenue estimates increase by 25%

Price target decreased to US$12.14

Consensus revenue estimates increase by 34%

Third quarter 2022 earnings released: US$0.72 loss per share (vs US$1.17 loss in 3Q 2021)

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Price target decreased to US$16.35

Consensus revenue estimates increase by 246%

Zymeworks Inc. to Report Q3, 2022 Results on Nov 08, 2022

Price target decreased to US$17.98

Zymeworks Inc. Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) At European Society for Medical Oncology Annual Congress

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

Price target decreased to US$21.56

Zymeworks Inc. Appoints Mr. Neil Klompas as President

Zymeworks: A Roller Coaster Year

Zymeworks Inc. to Report Q2, 2022 Results on Aug 04, 2022

Zymeworks Inc. Appoints Dr. Paul Moore as Chief Scientific Officer, Effective July 18, 2022

Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2-Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022

All Blue Falcons FZE cancelled the acquisition of the remaining 94.56% stake in Zymeworks Inc. (NYSE:ZYME).

Zymeworks And The Blue Falcon Elucidation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$27.55

Alan Barge Would Serve on Zymeworks Inc.'s Board

Insider recently bought US$21m worth of stock

Zymeworks Inc. to Report Q1, 2022 Results on May 04, 2022